Clinical Trials in Ostrowiec Świętokrzyski, Poland
10 recruiting
Showing 1–19 of 19 trials
Recruiting
Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled318 locationsNCT06855498
Recruiting
Phase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Eczema
Pfizer150 enrolled41 locationsNCT06807268
Recruiting
Phase 2
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
Respiratory Syncytial Virus Infections
Shionogi192 enrolled68 locationsNCT07214571
Recruiting
Phase 3
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Asthma
Teva Branded Pharmaceutical Products R&D LLC2,700 enrolled393 locationsNCT06052267
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled98 locationsNCT05995964
Recruiting
Phase 4
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease
Sanofi218 enrolled58 locationsNCT07053423
Recruiting
Phase 2
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Alopecia Areata
Eli Lilly and Company60 enrolled29 locationsNCT07533006
Recruiting
Phase 2
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
VitiligoNon-Segmental Vitiligo (NSV)
Eli Lilly and Company60 enrolled35 locationsNCT07533019
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled597 locationsNCT07181109
Recruiting
Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Asthma
Sanofi1,147 enrolled236 locationsNCT06676319
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Moderate to Severe Asthma
Incyte Corporation240 enrolled83 locationsNCT05851443
Recruiting
Phase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Atopic Dermatitis
Pfizer500 enrolled31 locationsNCT06807281
Recruiting
Phase 3
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
Molecular Mechanisms of Pharmacological ActionPeripheral Nervous System AgentsNeurotransmitter Agents+7 more
Merz Aesthetics GmbH300 enrolled26 locationsNCT07210463
Recruiting
Phase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
LEO Pharma195 enrolled72 locationsNCT06311682
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966
Recruiting
Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
Severe Asthma
Upstream Bio Inc.436 enrolled84 locationsNCT06966479
Recruiting
Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
Refractory or Unexplained Chronic Cough
Nocion Therapeutics455 enrolled107 locationsNCT06504446
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NonSegmental Vitiligo
Incyte Corporation250 enrolled86 locationsNCT06804811
Recruiting
Phase 3
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Vitiligo
Pfizer400 enrolled74 locationsNCT06163326